Decreased expression of peroxiredoxin 6 in a mouse model of ethanol consumption.
Alcoholic liver disease is multifactorial and oxidative stress is believed to play an intimate role in the initiation and progression of this pathology. The goals of this study were to investigate the effect of chronic ethanol treatment on inducing hepatic oxidative stress and peroxiredoxin 6 expression. After 9 weeks of treatment with an ethanol-containing diet, significant increases in serum ALT activity, liver to body weight ratio, liver triglycerides, CYP2E1 protein expression, and CYP2E1 activity were observed. Chronic ethanol feeding resulted in oxidative stress as evidenced by decreases in hepatic glutathione content and increased deposition of 4-hydroxynonenal and 4-oxononenal protein adducts. In addition, novel findings of decreased PRX6 protein and mRNA and increased levels of carbonylated PRX6 protein were observed in the ethanol-treated animals compared to the pair-fed controls. Lastly, NF-kappaB activity was found to be significantly increased in the ethanol-treated animals. Concurrent with the increase in NF-kappaB activity, decreases in both MEK1/2 and ERK1/2 phosphorylation were also observed in the ethanol-treated animals compared to the pair-fed controls. Together, these data demonstrate that chronic ethanol treatment results in oxidative stress, implicating NF-kappaB activation as an integral mechanism in the negative regulation of PRX6 gene expression in the mouse liver.
Department of Pharmaceutical Sciences, School of Pharmacy, University of Colorado Health Sciences Center, Denver, CO 80262, USA.
James R
JR
Roede
Benjamin J
BJ
Stewart
Dennis R
DR
Petersen
D000428:Alcohol Drinking / Q000378:metabolism*; D000447:Aldehydes / Q000378:metabolism; D000818:Animals; D019392:Cytochrome P-450 CYP2E1 / Q000378:metabolism; D004032:Diet; D000431:Ethanol / Q000633:toxicity*; D015870:Gene Expression; D005978:Glutathione / Q000378:metabolism; D007150:Immunohistochemistry; D008099:Liver / Q000378:metabolism* / Q000473:pathology; D008297:Male; D051379:Mice; D020928:Mitogen-Activated Protein Kinases / Q000378:metabolism; D023421:Models, Animal; D016328:NF-kappa B / Q000378:metabolism; D018384:Oxidative Stress / Q000187:drug effects; D054465:Peroxiredoxin VI / Q000235:genetics / Q000378:metabolism*; D010766:Phosphorylation; D016133:Polymerase Chain Reaction; D050050:Protein Carbonylation / Q000187:drug effects; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D014280:Triglycerides / Q000378:metabolism
D000447:Aldehydes; D016328:NF-kappa B; D012333:RNA, Messenger; D014280:Triglycerides; D000431:Ethanol; D054465:Peroxiredoxin VI; C515983:Prdx6 protein, mouse; D019392:Cytochrome P-450 CYP2E1; D020928:Mitogen-Activated Protein Kinases; D005978:Glutathione; C027576:4-hydroxy-2-nonenal